Clinical Trial Update: A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II trial of MLN8237 in metastatic castration-resistant and neuroendocrine prostate cancer completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Prostate Cancer
• Prostate Adenocarcinoma
• Small Cell Prostate Cancer

Drugs mentioned

• MLN8237 (alisertib)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-11-29